Please wait while we load the requested 10-Q report or click the link below:
Commercially launched the ICELL8™ Single Cell System at the American Society of Human Genetics annual meeting
Successfully completed a public offering of WaferGen securities that raised gross proceeds of $17.25 million to support research and development and commercialization activities for our single cell products, as well as for sales and marketing activities and for general corporate and working capital purposes
Presented results from the ICELL8™ Single Cell System at the Single Cell Genomics Conference in Utrecht, The Netherlands, that included work from early access collaborators at The University of Texas MD Anderson Cancer Center
Obtained from the U.S. Patent and Trademark Office a patent and a notice of allowance for a patent application, each with method and system claims utilizing multi-well chips, providing greater strength for WaferGen’s core SmartChip™ products and applications, including the ICELL8™ Single Cell System
Signed a supply agreement with Reprogenetics for use of WaferGen’s Apollo 324™ Next Generation Sequencing (NGS) sample preparation system to enable automation of NGS library preparation for Preimplantation Genetic Screening testing used in in vitro fertilization
SmartChip platform selected by Annoroad for high-throughput target enrichment of BRCA1 and BRCA2 genes, SNP genotyping services and library quantification for NGS
The following information was filed by Wafergen Biosystems, Inc. (WGBS) on Tuesday, November 10, 2015 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Wafergen Biosystems, Inc.'s financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Wafergen Biosystems, Inc..